These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35007884)

  • 1. Efficacy of levetiracetam in STXBP1 encephalopathy with different phenotypic and genetic spectra.
    Wang QH; Cao JJ; Wang YY; Zhang MN; Liu LY; Wang J; Lu Q; He W; Shen YW; Chen HM; Luo XM; Chen Q; Zou LP
    Seizure; 2022 Feb; 95():64-74. PubMed ID: 35007884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation.
    Dilena R; Striano P; Traverso M; Viri M; Cristofori G; Tadini L; Barbieri S; Romeo A; Zara F
    Brain Dev; 2016 Jan; 38(1):128-31. PubMed ID: 26212315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and genetic characteristics of children with STXBP1 encephalopathy].
    Cao JJ; Ji XN; Mao YY; Zhang PP; Liu WT; Zhang HZ; Ding N; Chen Q
    Zhonghua Er Ke Za Zhi; 2020 Jun; 58(6):493-498. PubMed ID: 32521962
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic benefits of ACTH and levetiracetam in STXBP1 encephalopathy with a de novo mutation: A case report and literature review.
    Liu S; Wang L; Cai XT; Zhou H; Yu D; Wang Z
    Medicine (Baltimore); 2018 May; 97(18):e0663. PubMed ID: 29718889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-phenotype correlations of STXBP1 pathogenic variants and the treatment choices for STXBP1-related disorders in China.
    Kessi M; Chen B; Shan LD; Wang Y; Yang L; Yin F; He F; Peng J; Wang G
    BMC Med Genomics; 2023 Mar; 16(1):46. PubMed ID: 36882827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein instability, haploinsufficiency, and cortical hyper-excitability underlie STXBP1 encephalopathy.
    Kovacevic J; Maroteaux G; Schut D; Loos M; Dubey M; Pitsch J; Remmelink E; Koopmans B; Crowley J; Cornelisse LN; Sullivan PF; Schoch S; Toonen RF; Stiedl O; Verhage M
    Brain; 2018 May; 141(5):1350-1374. PubMed ID: 29538625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo mutations of STXBP1 in Chinese children with early onset epileptic encephalopathy.
    Li T; Cheng M; Wang J; Hong S; Li M; Liao S; Xie L; Jiang L
    Genes Brain Behav; 2018 Nov; 17(8):e12492. PubMed ID: 29896790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study.
    Del Bianco C; Placidi F; Liguori C; Mari L; Ulivi M; Ornello R; Pisani A; Mercuri NB; Izzi F
    Epilepsy Behav; 2019 May; 94():178-182. PubMed ID: 30959275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levetiracetam monotherapy--outcomes from an epilepsy clinic.
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Seizure; 2011 Sep; 20(7):554-7. PubMed ID: 21531583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STXBP1 encephalopathy: A neurodevelopmental disorder including epilepsy.
    Stamberger H; Nikanorova M; Willemsen MH; Accorsi P; Angriman M; Baier H; Benkel-Herrenbrueck I; Benoit V; Budetta M; Caliebe A; Cantalupo G; Capovilla G; Casara G; Courage C; Deprez M; Destrée A; Dilena R; Erasmus CE; Fannemel M; Fjær R; Giordano L; Helbig KL; Heyne HO; Klepper J; Kluger GJ; Lederer D; Lodi M; Maier O; Merkenschlager A; Michelberger N; Minetti C; Muhle H; Phalin J; Ramsey K; Romeo A; Schallner J; Schanze I; Shinawi M; Sleegers K; Sterbova K; Syrbe S; Traverso M; Tzschach A; Uldall P; Van Coster R; Verhelst H; Viri M; Winter S; Wolff M; Zenker M; Zoccante L; De Jonghe P; Helbig I; Striano P; Lemke JR; Møller RS; Weckhuysen S
    Neurology; 2016 Mar; 86(10):954-62. PubMed ID: 26865513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype and phenotype spectrum of 10 children with
    Dong M; Zhang T; Hu R; Li M; Wang G; Liu X
    Front Pediatr; 2022; 10():1010886. PubMed ID: 36440324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delineating clinical and developmental outcomes in STXBP1-related disorders.
    Xian J; Thalwitzer KM; McKee J; Sullivan KR; Brimble E; Fitch E; Toib J; Kaufman MC; deCampo D; Cunningham K; Pierce SR; Goss J; Rigby CS; Syrbe S; Boland M; Prosser B; Fitter N; Ruggiero SM; Helbig I
    Brain; 2023 Dec; 146(12):5182-5197. PubMed ID: 38015929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epileptic and nonepileptic features in patients with early onset epileptic encephalopathy and STXBP1 mutations.
    Milh M; Villeneuve N; Chouchane M; Kaminska A; Laroche C; Barthez MA; Gitiaux C; Bartoli C; Borges-Correia A; Cacciagli P; Mignon-Ravix C; Cuberos H; Chabrol B; Villard L
    Epilepsia; 2011 Oct; 52(10):1828-34. PubMed ID: 21770924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy.
    Schelhaas M; Wegner I; Edens M; Wammes-Van Der Heijden E; Touw D; Ter Horst P
    Neurology; 2023 Jan; 100(2):e172-e181. PubMed ID: 36257713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.
    Ben-Menachem E; Falter U
    Epilepsia; 2000 Oct; 41(10):1276-83. PubMed ID: 11051122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the anticonvulsant activity of levetiracetam dose-dependent?
    Lamouret V; Kurth C; Intravooth T; Steinhoff BJ
    Seizure; 2020 Dec; 83():197-202. PubMed ID: 33197757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.